Endo International plc (ENDP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

100 ENDO BOULEVARD CHADDS FORD, PA 19317

Develops and markets a portfolio of branded and generic pharmaceutical products primarily for the treatment of pain, including Percocet and Percodan. The company's products are marketed primarily to wholesale drug distributors and chain and independent retail pharmacists.

Data as of 2020-07-04
Market Cap801.67 Million Shares Outstanding223.103 Million Avg 30-day Volume5.963 Million
P/E Ratio Dividend Yield EPS-1.23
Price/Sales0.346 Price cash flow ratio3.2 Price free cash flow ratio36.0
Book Value-3.21 Price to Tangible Book-0.12 Alpha-0.04
Short Interest Ratio % Short Interest to Float R-squared0.099631
BETA1.53145 52-week High/Low7.1 / 1.97 Stddev0.206614
View SEC Filings from ENDP instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 1 1 (0.07%)
13F Filers holding this stock: 180 52 (3.41%)
Aggregate 13F shares on 03/31/2020: 189.007 Million 100.554 Million
Aggregate 13F shares on 12/31/2019: 206.31 Million 108.563 Million
Percent change: -8.39% -7.38%
Funds creating new positions: 26 13
Funds Adding to an existing position: 55 15
Funds closing out their position: 41 20
Funds reducing their position: 70 20
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ENDP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ENDP BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

UPADHYAY SUKETU EXEC. VP, CFO

  • Officer
2,576 2020-07-01 0

CIAFFONI JOSEPH PRESIDENT AND CEO

  • Officer
  • Director
191,404 2020-07-01 0

HIGGINS ARTHUR J

  • Director
19,814 2020-06-30 0

LAVISCOUNT JOYCE N CFO AND COO

  • Officer
100,347 2020-06-30 0

ROWLAND CHARLES A JR

  • Director
3,562 2020-06-24 0

HUTSON NANCY J

  • Director
0 2020-06-18 1

LEVIN ALAN G

  • Director
0 2020-06-17 0

SMITH JILL D.

  • Director
11,207 2020-06-14 0

MONTAGUE WILLIAM P

  • Director
106,137 2020-06-12 1

HYATT MICHAEL

  • Director
330,639 2020-06-12 1

KIMMEL ROGER H

  • Director
216,575 2020-06-12 2

COOKE SHANE

  • Director
94,320 2020-06-12 1

BARBERIO MARK G

  • Director
13,266 2020-06-12 2

MCHUGH JULIE

  • Director
8,100 2020-06-11 0

SCODARI JOSEPH C

  • Director
0 2020-06-10 0

WYSENSKI NANCY

  • Director
0 2020-05-20 0

NASH DAVID

  • Director
12,355 2020-04-10 0

MALETTA MATTHEW JOSEPH EVP, CHIEF LEGAL OFFICER

  • Officer
182,700 2020-04-02 5

CAMPANELLI PAUL

  • Director
1,074,985 2020-04-02 5

COUGHLIN TERRANCE J EVP, CHIEF OPERATING OFFICER

  • Officer
337,507 2020-04-02 5

COLEMAN BLAISE PRESIDENT, CEO

  • Officer
  • Director
185,815 2020-04-02 4

BARRY PATRICK A EVP & PRES,GLOBAL COMM OPS

  • Officer
88,077 2020-04-02 5

GARELLA RAHUL EVP, INTL PHARMACEUTICALS

  • Officer
50,991 2020-04-02 6

BOYLE JACK D. SVP, CONTROLLER

  • Officer
34,817 2020-04-02 4

BRADLEY MARK T. EVP, CHIEF FINANCIAL OFFICER

  • Officer
32,862 2020-04-02 3

CIARICO DOMENICO EVP & CHIEF COMMERCIAL OFFICER

  • Officer
13,405 2020-03-29 3

GERGEL IVAN P.

  • Director
0 2020-03-20 0

NICHOL CARRIE ANN VP, CONTROLLER & CAO

  • Officer
0 2020-02-21 1

MEANWELL CLIVE CHIEF INNOVATION OFFICER

  • Officer
  • Director
0 2020-01-06 0

INGRAM DOUGLAS S PRESIDENT & CEO

  • Officer
  • Director
395,012 2019-12-31 0

DEGOLYER DONALD W

  • Director
0 2019-08-22 0

MANSUKANI SHARAD

  • Director
71,523 2019-06-12 0

PERA ANTONIO R PRESIDENT, PAR PHARMACEUTICAL

  • Officer
65,648 2019-04-02 0

FARHAT CAMILLE CHIEF EXECUTIVE OFFICER

  • Officer
0 2019-03-08 0

SISITSKY TODD BENJAMIN

  • Director
0 2018-10-10 0

RUDIO DANIEL SVP, CONTROLLER

  • Officer
9,669 2018-02-23 0

SWEENEY EDWARD J INTERIM CFO

  • Officer
0 2017-06-01 0

VARGHESE HEMANTH JACOB PRES. INTERNATIONAL PHARMA

  • Officer
4,350 2016-04-29 0

DE SILVA RAJIV PRESIDENT & CEO

  • Officer
  • Director
355,010 2016-03-18 0

SPENGLER WILLIAM

  • Director
48,835 2016-03-17 0

HALL SUSAN EVP, CSO, GLOBAL HEAD OF R&D

  • Officer
4,826 2016-03-11 0

LORTIE BRIAN PRESIDENT BRANDED PHARMA

  • Officer
24,504 2016-03-02 0

MANOGUE CAROLINE B EXEC. V.P.,CHIEF LEGAL OFFICER

  • Officer
43,100 2015-04-07 0

DELUCCA JOHN

  • Director
32,343 2015-03-04 0

HOLVECK DAVID PRESIDENT & CEO

  • Officer
  • Director
29,528 2013-02-26 0

D. E. SHAW VALENCE PORTFOLIOS, L.L.C.

D. E. SHAW & CO, L.P.

SHAW DAVID E

  • 10% Owner
  • SEE FOOTNOTE 4.SEE FOOTNOTE 4.SEE FOOTNOTE 4.
No longer subject to file 2009-03-05 0

DE ROSEN MICHEL

  • Director
137,100 2008-11-07 0

HORNER GEORGE F III

  • Director
5,003 2008-03-12 0

LEE DAVID A H EXEC. V.P AND CSO

  • Officer
2,801 2008-02-21 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

HUTSON NANCY J - Director

2020-06-12 A 25,511 a 103,464 91,219.00 direct

KIMMEL ROGER H - Director

2020-06-12 F 12,245 $3.43 d 136,575 216,575.00 direct

HYATT MICHAEL - Director

2020-06-12 A 25,511 a 332,509 330,639.00 direct

BARBERIO MARK G - Director

2020-06-12 F 12,245 $3.43 d 13,266 13,266.00 direct

COOKE SHANE - Director

2020-06-12 A 25,511 a 107,585 94,320.00 direct

KIMMEL ROGER H - Director

2020-06-12 A 25,511 a 148,820 216,575.00 direct

MONTAGUE WILLIAM P - Director

2020-06-12 F 12,245 $3.43 d 106,137 106,137.00 direct

BARBERIO MARK G - Director

2020-06-12 A 25,511 a 25,511 13,266.00 direct

HUTSON NANCY J - Director

2020-06-12 F 12,245 $3.43 d 91,219 91,219.00 direct

HYATT MICHAEL - Director

2020-06-12 F 12,245 $3.43 d 320,264 330,639.00 direct

MONTAGUE WILLIAM P - Director

2020-06-12 A 25,511 a 118,382 106,137.00 direct

COOKE SHANE - Director

2020-06-12 F 13,265 $3.43 d 94,320 94,320.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments